Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Hyperfine Inc (HYPR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.69-8.65%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HYPR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash burn of $26-$28M in 2026 | The company aims to control cash burn near $26-$28M despite losses. | Intact | Cash burn exceeds $28M in FY26 | Free cash flow: $-7.298M FY2026-Q2; GAAP. Published target: Cash burn between $26M and $28M. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-7,298,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
HYPR is a high-risk growth company, not yet a proven durable compounder, because it remains loss-making. Its long-term thesis is on watch: revenue execution is on track, while financial performance remains below its industry cohort.
The valuation carries a durable premium of 1.75 times versus peers, while the expectations gap is negative, suggesting expectations are ahead of what the evidence supports. The pricing tag is justified and fragility is low, but the premium leaves room for concern if execution weakens.
Near term, revenue growth is tracking management’s 2026 goal: quarterly revenue rose 44.8% year over year in Q2, and preliminary Q3 revenue was higher sequentially. Cash burn has improved year over year, though progress toward the full-year goal is mixed, and the company remains loss-making. The next guidance update, employment trends, and a recent delisting-rule notice are risks to watch.
The multi-year view depends on HYPR sustaining its revenue growth while reducing cash burn and expanding internationally. A guidance cut or weaker jobs data could weigh on the near-term business backdrop, while continued strength from healthcare sector bellwethers could support sector momentum. The evidence for international revenue contribution is limited.
Over the next 1 to 3 years, HYPR’s growth execution offers a constructive element, but losses, elevated risk, a peer premium, and weaker relative performance leave the thesis unresolved. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “• Management continues to expect cash burn 1 for the full year 2026 to be approximately $26 to $28 million, representing a 10% decline at the midpoint as compared to full year 2025.” “Cash and cash equivalents were $40.8 million as of March 31, 2026 and $43.5 million as of June 30, 2026 and are preliminarily expected, on an unaudited basis, to be approximately $37.9 million as of September 30, 2026; net financing proceeds in the aggregate were $10.6 million for the quarter ended June 30, 2026 and $0.0 million for the quarter ended September 30, 2026.”
Improve gross profit margins | Gross profit shows early improvement, supporting future margin gains. | Intact | Gross profit falls below 2026-Q1 level of $2.0M | Gross profit: $1.98M FY2026-Q2; GAAP. Published target: Sustain or improve gross profit above 2026-Q1 level. Target period is not explicitly aligned with this observation. Aug 6, 20261,980,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Gross profit for the second quarter of 2026 was $2.0 million, compared to $1.3 million in the second quarter of 2025, representing 50.7% gross margin in the second quarter of 2026, compared to 49.3% gross margin in the second quarter of 2025.” “• Gross profit for the first quarter of 2026 was $1.98 million, compared to $0.88 million in the first quarter of 2025, representing 51% gross margin in the first quarter of 2026, compared to 41% gross margin in the first quarter of 2025.” Delivery assessment Nov 4, 2026 |
Achieve $20-$22M revenue in 2026 | A primary condition in Hyperfine Inc's published investment case. The stated target is >= $20M total revenue. | Intact | Revenue falls below $20M in FY26 | Revenue: $3.904M FY2026-Q2; GAAP. Published target: >= $20M total revenue. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20263,904,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Results • Revenues for the second quarter of 2026 were $3.9 million, increasing 44.8% compared to $2.7 million in the second quarter of 2025.” “The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.34 → $-0.32 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-07-25 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-07-26 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-07-27 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-07-28 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-07-29 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-07-30 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-07-31 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-08-01 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-02 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-08-03 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-08-04 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-08-05 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-08-06 | $-0.34 | $26,300,000 | 1 / 2 |
| 2026-08-07 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-08 | $-0.34 | $26,250,000 | 1 / 2 |
| 2026-08-09 | $-0.34 | $26,250,000 | 1 / 2 |
| 2026-08-10 | $-0.34 | $26,250,000 | 1 / 2 |
| 2026-08-12 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-13 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-14 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-15 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-16 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-17 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-18 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-19 | $-0.34 | $26,291,000 | 1 / 2 |
| 2026-08-20 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-08-21 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-08-22 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-23 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-24 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-25 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-26 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-27 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-28 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-29 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-30 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-08-31 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-01 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-02 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-03 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-04 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-05 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-06 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-07 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-08 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-09 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-10 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-11 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-12 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-13 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-14 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-15 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-16 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-17 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-18 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-19 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-20 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-21 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-22 | $-0.32 | $26,255,000 | 1 / 2 |
| 2026-09-23 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-24 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-25 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-26 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-27 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-28 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-29 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-09-30 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-01 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-02 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-03 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-04 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-05 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-06 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-07 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-08 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-09 | $-0.32 | $26,255,500 | 1 / 2 |
| 2026-10-10 | $-0.32 | $26,255,500 | 1 / 2 |
| 2026-10-11 | $-0.32 | $26,255,500 | 1 / 2 |
| 2026-10-12 | $-0.32 | $26,255,500 | 1 / 2 |
| 2026-10-13 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-14 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-15 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-16 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-17 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-18 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-19 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-20 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-21 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-22 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-23 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-24 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-25 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-26 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-27 | $-0.32 | $26,250,000 | 1 / 2 |
| 2026-10-28 | $-0.32 | $26,833,333 | 2 / 2 |
| 2026-10-29 | $-0.32 | $26,833,333 | 2 / 3 |
| 2026-10-30 | $-0.32 | $26,833,333 | 2 / 3 |
| 2026-10-31 | $-0.32 | $26,833,333 | 2 / 3 |
| 2026-11-01 | $-0.32 | $26,833,333 | 2 / 3 |
| 2026-11-02 | $-0.32 | $26,833,333 | 2 / 3 |
| 2026-11-03 | $-0.32 | $26,833,333 | 2 / 3 |
| 2026-11-04 | $-0.32 | $26,833,333 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.